Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Unknown 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Lymphoid 1

Conditions

Carcinoma, Renal Cell 2Triple Negative Breast Neoplasms 1Papillomavirus Infections 1Pancreatic Neoplasms 1Ovarian Neoplasms 1Lymphoma, Large-Cell, Anaplastic 1Lymphoma, B-Cell 1Leukemia, B-Cell 1Kidney Neoplasms 1Hodgkin Disease 1High Grade Cervical Intraepithelial Neoplasia 1Carcinoma, Non-Small-Cell Lung 1Breast Neoplasms 1Adenocarcinoma 1

Interventions

Brentuximab Vedotin 16ceritinib 3Rifampin 3brigatinib 2Vincristine 2Prednisone 2Gemcitabine 2Doxorubicin 2Cyclophosphamide 2Crizotinib 210-propargyl-10-deazaaminopterin 2tislelizumab 1repotrectinib 1relatlimab 1ontuxizumab 1iratumumab 1entrectinib 1brincidofovir 1belinostat 1alectinib 1XMAB-2513 1WW Domain-Containing Oxidoreductase 1Vitamin B 12 1Suspensions 1Nivolumab 1Midazolam 1MLN 8237 1Ketoconazole 1Itraconazole 1Folic Acid 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
INDUSTRY × Lymphoma, Large-Cell, Anaplastic × Biological Products × Clear all
NCT03383965 2017-12-27

CD30 Targeted CAR-T in Treating CD30-Expressing Lymphomas

Immune Cell, Inc.

Phase 1 Unknown
20 enrolled
Lymphoid

Hodgkin Disease, Lymphoma, Large-Cell, Anaplastic

Data powered by HemOnc (CC BY 4.0) Colophon âš¡